title: Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: the role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven.
authors.affiliation: Division of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
authors.forename: Vamsi
authors.initials: V
authors.lastname: Krishna
authors.forename: George A
authors.initials: GA
authors.lastname: Diamond
authors.forename: Sanjay
authors.initials: S
authors.lastname: Kaul
mesh_terms: D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005820:Genetic Testing / Q000592:standards*; D005838:Genotype; D006801:Humans; D010597:Pharmacogenetics / Q000592:standards*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D010979:Platelet Function Tests / Q000592:standards*; D015995:Prevalence; D011379:Prognosis; D058921:Purinergic P2Y Receptor Antagonists / Q000627:therapeutic use; D058925:Receptors, Purinergic P2Y12 / Q000235:genetics / Q000378:metabolism; D012307:Risk Factors; D013927:Thrombosis / Q000175:diagnosis* / Q000453:epidemiology / Q000517:prevention & control*; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D005343:Fibrinolytic Agents; C548576:P2RY12 protein, human; D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D058925:Receptors, Purinergic P2Y12; D000077144:Clopidogrel; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine; D001241:Aspirin